Ashley L. Sumrall

Hematology | Oncology

1021 Morehead Medical Drive
Suite 6100
Charlotte, NC 28204

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

340B Drug Pricing Program: An Updated ASCO Policy Statement.

340B Drug Pricing Program: An Updated ASCO Policy Statement.

Journal: JCO oncology practice

Published: May 05, 2026

Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Journal: Cancer discovery

Published: January 30, 2025

Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas.

Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas.

Journal: Neuro-oncology advances

Published: November 18, 2024

Using Federal, State, and Grassroots Advocacy to Effect Change in Cancer Care Delivery and Patient Outcomes in the United States.

Using Federal, State, and Grassroots Advocacy to Effect Change in Cancer Care Delivery and Patient Outcomes in the United States.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 23, 2024

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 09, 2024

Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.

Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.

Journal: Medical oncology (Northwood, London, England)

Published: March 30, 2023

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.

Journal: Cancer discovery

Published: January 29, 2023

Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.

Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.

Journal: Neuro-oncology advances

Published: July 13, 2022

Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment.

Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment.

Journal: Anticancer research

Published: May 25, 2022

Defining targets to improve care delivery for T4 larynx squamous cell carcinoma.

Defining targets to improve care delivery for T4 larynx squamous cell carcinoma.

Journal: Laryngoscope investigative otolaryngology

Published: May 25, 2022

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.

Journal: Neuro-oncology

Published: May 05, 2022

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.

Journal: Neuro-oncology

Published: April 14, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026